60 Degrees Pharma Grants University Of Kentucky Right Of Reference To ARAKODA NDA For Phase IIb Clinical Study Of SJ733 For Vivax Malaria; Study Will Combine SJ733 With Single Dose Of Tafenoquine
Portfolio Pulse from Benzinga Newsdesk
60 Degrees Pharma has granted the University of Kentucky the right of reference to its New Drug Application (NDA) for ARAKODA. This will facilitate a Phase IIb clinical study of SJ733 for Vivax malaria, combining SJ733 with a single dose of Tafenoquine.
August 12, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
60 Degrees Pharma has granted the University of Kentucky the right of reference to its NDA for ARAKODA, enabling a Phase IIb clinical study of SJ733 for Vivax malaria.
The granting of the right of reference to the NDA for ARAKODA by 60 Degrees Pharma (SXTP) is a significant step in advancing the clinical study of SJ733 for Vivax malaria. This partnership with the University of Kentucky could lead to positive developments and potential future approvals, likely boosting investor confidence in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100